Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG0803)

Author： Wu Y.-L.   Zhou C.   Cheng Y.   Lu S.   Chen G.-Y.   Huang C.   Huang Y.-S.   Yan H.-H.   Ren S.   Liu Y.   Yang J.-J.  

Publisher： Oxford University Press

ISSN： 0923-7534

Source： Annals of Oncology, Vol.24, Iss.4, 2013-04, pp. : 993-999

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

By Rossi David  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 231-235

Springer Publishing Company

Access to resources Recommend Favorite

Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases - a phase II study of the EORTC Lung Cancer Group (08965)

By Dziadziuszko R.   Ardizzoni A.   Postmus P.E.   Smit E.F.   Price A.   Debruyne C.   Legrand C.   Giaccone G.   on behalf of the EORTC Lung Cancer Group  

European Journal of Cancer, Vol. 39, Iss. 9, 2003-06 ,pp. : 1271-1276

Elsevier

Access to resources Recommend Favorite

Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: A phase II trial

By Tas Faruk   Demir Cumhur   Camlica Hakan   Ustuner Zeki   Topuz Erkan  

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 233-240

Humana Press, Inc

Access to resources Recommend Favorite

Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy

By Mori Kiyoshi   Kamiyama Yukari   Kondo Tetsuro   Kano Yasuhiko   Kodama Tetsuro  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 189-195

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

By Motoshima Kohei   Nakamura Yoichi   Sano Kazumi   Ikegami Yoji   Ikeda Takaya   Mizoguchi Kosuke   Takemoto Shinnosuke   Fukuda Minoru   Nagashima Seiji   Iida Tetsuya   Tsukamoto Kazuhiro   Kohno Shigeru  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1299-1304

Springer Publishing Company

Access to resources Recommend Favorite